2006 Re and So
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
UCB SA (Incorporated with Limited Liability in Belgium) As Issuer
Base Prospectus dated 8 March 2021 UCB SA (incorporated with limited liability in Belgium) as Issuer EUR 5,000,000,000 Euro Medium Term Note Programme Due from one month from the date of original issue This base prospectus (the “Base Prospectus”) relating to the EUR 5,000,000,000 Euro Medium Term Note Programme (the “Programme”) of UCB SA, a limited liability company (société anonyme) incorporated under the laws of Belgium, having its registered office at Allée de la Recherche 60, B-1070 Brussels and registered with the Crossroads Bank for Enterprises under number 0403.053.608 (“UCB”, or the “Issuer”) is valid, for the purpose of the admission to trading and listing of the Notes (as defined below) on the regulated market of Euronext Brussels or on another regulated market in the European Economic Area (the “EEA”), for a period of twelve months from the date of approval. Any Notes issued under the Programme are issued subject to the provisions set out herein. Under the Programme, the Issuer, subject to compliance with all relevant laws, regulations and directives, may from time to time issue Euro Medium Term Notes (the “Notes”) as may be agreed between the Issuer and the relevant Dealer (as defined below). The minimum Specified Denomination of Notes shall be EUR 100,000 (or its equivalent in other currencies).The maximum aggregate nominal amount of Notes outstanding will not at any time exceed EUR 5,000,000,000 (or the equivalent in other currencies). This Base Prospectus has been approved as a base prospectus for the purposes of Article 8 of Regulation 2017/1129 (as amended, the “Prospectus Regulation”) on 8 March 2021 by the Belgian Financial Services and Markets Authority (the “FSMA”) in its capacity as competent authority in accordance with Article 20 of the Prospectus Regulation. -
Stronger Together Annual Report 2007/ 08 the NA Group
Stronger together Annual Report 2007/ 08 The NA Group Norddeutsche Affi nerie is the leading integrated copper group in Europe. Our core competence lies in the production and processing of copper, the material of the future. We are excellently represented all along the value added chain of copper from raw material processing and cathode production through to the production of copper products. We are also outstandingly positioned worldwide in the recycling of copper and other metals. Copper Production Copper Processing Cathodes, precious Shapes, wire rod, wires, metals and by-products strips and profi les In the Copper Production Segment we produce As an integrated copper group, we process our copper copper cathodes from copper concentrates and recy- cathodes into a variety of copper products, fi rst and cled raw materials. Both types of raw materials are foremost electrolytic copper wire rod for the cable and sourced internationally; recycled raw materials are wire industry. In addition, we produce continuous also procured in Germany. Our earnings are primarily cast shapes from cathodes for the market and for pro- determined by treatment and refi ning charges that cessing internally into pre-rolled strip as well as strips, are agreed with the raw material suppliers as the pro- shaped wires and profi les. Our revenues are deter- cessing fee. Our copper cathodes fulfi l the very high mined inter alia by processing fees that refl ect the quality requirements of the metal exchanges. The value added. Copper Production Segment also includes the produc- tion of precious metals, sulphuric acid, iron silicate products and other metal and chemical products from the by-elements of copper in the raw materials. -
Integrated Annual Report 2020
Amber, living with psoriasis INTEGRATED ANNUAL REPORT 2020 ADAPTING FOR BETTER CARE INTEGRATED ANNUAL REPORT 2020 ADAPTING FOR BETTER CARE Welcome to our Integrated Annual Report 2020! Our Integrated Annual Report 2020 – Adapting for Better Care – aims to provide all interested stakeholders with the best pos- sible information on how UCB is creating value for patients with severe diseases and about how we care for our employees, for communities, and for our planet, now and into the future. About this report This Integrated Annual Report 2020 includes the management report in accordance with article 12 of the Royal Decree of 14 November 2007 relating to the obligations of issuers of finan- cial instruments admitted to trading on a regulated market. All information required to be included in such management report pursuant to articles 3:6 and 3:32 of the Belgian Code of Com- panies and Associations (i.e. Corporate Governance Statement – Remuneration Report included -, Business Performance Review and UCB’s Statement on extra-financial1 information) is reported throughout all different sections of this Integrated Annual Re- port. This Integrated Annual Report together with the materiality assessment have been prepared in accordance with the Global Reporting Standards core option and extra-financial information is audited by a third party. 1 ‘Extra-financial’ is the term used by UCB for information commonly referred to as ‘non-financial’. UCB | Integrated Annual Report 2020 3 Index Key Figures 6 UCB At a Glance 8 Letter to our stakeholders -
September 2020 Introduction to Umicore We Are a Global Materials Technology and Recycling Group
Umicore Investor Presentation September 2020 Introduction to Umicore We are a global materials technology and recycling group One of three global A leading supplier of key The world’s leading leaders in emission control materials for rechargeable recycler of complex waste catalysts for light-duty and batteries used in electrified streams containing heavy-duty vehicles and transportation and portable precious and other for all fuel types electronics valuable metals 3 With a unique position in clean mobility materials and recycling Internal Plug-In Hybrid Combustion Engine Electric Vehicle Umicore provides: Umicore provides: Emission control catalysts Battery cathode materials and emission control catalysts Full Electric Vehicle Fuel cells Umicore provides: Umicore provides: Battery cathode materials Electro-catalyst and battery cathode materials Present across all drive trains and offering sustainable closed- loop services 4 Built on sound foundations Supportive Unique business Industry leader in megatrends & model sustainability legislation resource scarcity more stringent emission control electrification recyclingrecycling of the automobile We help improve air quality, make electrified transport possible and tackle resource scarcity 5 5 With a robust financial performance and a global presence Key figures (FY 2019) Adj. Revenues EBITDA € 3.4 bn € 753 m Adj. EBIT ROCE € 509 m 12.6% 40% - Europe Revenues* by Clean geography 14% - North America mobility and R&D Recycling 6% of 4% - South America 75% of revenues revenues 39% - Asia-Pacific -
Umicore Intends to Launch Squeeze-Out for Remainder of Agosi
Press release 3 February 2021 – 08:30 am CET Umicore intends to launch squeeze-out for remainder of Agosi shares Umicore has informed its listed subsidiary Allgemeine Gold- und Silberscheideanstalt AG (“Agosi”) that it intends to purchase the 8.8 % shares it does not yet own from Agosi’s minority shareholders through a merger squeeze-out in accordance with German law. To determine the cash compensation for Agosi’s minority shareholders, a valuation of Agosi will be carried out by an independent valuer appointed by Umicore and a court-appointed auditor. Following a squeeze-out and subsequent delisting, Umicore would have flexibility to consider strategic options for the Jewelry & Industrial Metals activities within Agosi. These activities perform well from a commercial and financial point of view and Umicore wants to explore the best conditions for their further development. Umicore expects that the merger squeeze-out would be resolved upon by the general meeting of Agosi in the second or third quarter of 2021. Note to the editor: Umicore acquired Agosi upon the acquisition of the Precious Metals Group (“PMG”) in 2003 and currently holds 91.2 % of its shares. Agosi shares are listed on the Munich Freiverkehr stock exchange. Agosi, headquartered in Pforzheim, Germany, has an international presence and offers the full precious metals cycle and other precious metals services for the jewelry and coin industries, as well as for various industrial applications in electrical engineering, in automotive, in the chemical industry and in medical technology. Agosi’s activities are integrated in Umicore’s Jewelry & Industrial Metals business unit and one Agosi subsidiary is part of Umicore’s Electroplating business unit. -
2016 Dec Patricio Barrios RESUME
December 2016 RESUME – P. Barrios RESUME EDUCATION: BSc. Chemistry - University Seville, Spain MSc. Chemical Engineering - University Seville, Spain PhD. Chemistry - University Seville, Spain; Thesis: “Kinetics of the Copper Blow Stage during pyrometallurgical Copper-Making” (A Kinetic Model) Dipl. Environmental Eng. - Technical University Madrid, Spain Dipl. R&D Management - CSIC (High Counsel Scientist Research) Madrid, Spain Dipl. Business Administration -ESADE Barcelona, Spain, and The International Social Science Council Paris, France PROFESIONAL EXPERIENCE: January 2016 – Present: Aurubis AG; Principal Adviser – Primary Copper. Responsible to provide high level strategic advice to the EVP-Primary Copper BU which includes assisting on the overall direction and function of Business Development, participating on special projects, including liaison and development of key relationships with selected business partners. April 2008 – December 2015: Aurubis AG (new public company resulting from the merging of Cumerio and Norddeutsche Affinerie ,with operations and activities in 22 countries around Europe, North America and Asia, totaling 6400 employees and 13.8 Billion € revenues): Senior Vice President - Projects Primary Copper. Responsible for Primary Copper Business Unit’s growing projects, with main focus on new business opportunities and external projects. April 2006 – April 2008: Cumerio (public Belgian company resulting from the carve-out of the former Union Miniere’s Copper operations): Vice President Operations & ExCom Member. Full corporate responsibility for the Cumerio Group operations: Copper Refining BU and Copper Products BU with operations in Pirdop (Bulgaria), Olen (Belgium) and Avellino (Italy); totaling 1500 employees and 3.5 Billion € of revenues. 2005 – March 2006: Associated, as Senior Adviser- Non Ferrous Metals at Hatch Corporate Finance (HCF) International Advisers (formerly HB Advisers) –Hatch Group-; a London based leading corporate finance advisory firm focused exclusively on the metals and mining sectors worldwide. -
Dynavax Announces Full Enrollment of Phase II/III AIC Trial
Dynavax Announces Full Enrollment of Phase II/III AIC Trial BERKELEY, Calif., May 19 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today announced that its Phase II/III clinical trial of AIC for ragweed allergy, which started in late February 2004, has been fully enrolled. The double blind, placebo controlled study involves 462 subjects at 30 sites in the U.S. and will be completed over the next 18 months. The immunization schedule, consisting of six injections over six weeks, will be completed by June. The clinical trial is being conducted in collaboration with UCB Pharma, a European pharmaceutical company that markets XYZAL® and developed ZYRTEC®, the leading prescription anti- allergy drug worldwide. Dynavax and UCB signed a global licensing and commercialization agreement covering ragweed and grass allergy immunotherapies in February 2004. The primary endpoint of the Phase II/III ragweed study will be nasal symptoms scores after the second ragweed season in the late summer and early fall of 2005, with secondary endpoints assessing symptoms, medication use and quality of life in both the first and second year. A blinded interim analysis will be made in late 2004 to assess safety and the appropriateness of commencing a one-year Phase III trial in early 2005. "The collaboration with UCB has been very effective, with both organizations working diligently to advance our ragweed program," said Dr. Dino Dina, president and CEO of Dynavax. "The rapid enrollment of our ragweed trial, particularly given its size and stringent enrollment criteria, is an early indication of the level of interest that both investigators and patients have in this therapy. -
Lamotrigine Orally Disintegrating Tablet
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 3001-14 Program Step Therapy - Anticonvulsants Medication/Therapeutic Anticonvulsants – Class Depakote®, Depakote ER®, Felbatol, Keppra® , Keppra® XR®, Lamictal®, Lamictal XR®, Lamictal ODT®, lamotrigine extended-release, lamotrigine orally disintegrating tablet, Lyrica, Mysoline, Neurontin®, Onfi, Oxtellar™ XR*, Qudexy XR* (brand and authorized generic), Sabril, Spritam*, Topamax®, Trileptal®, Trokendi® XR*, Zonegran® P&T Approval Date 8/2010, 11/2010, 11/2011, 2/2013, 11/2013, 4/2014, 7/2014, 11/2014, 4/2015, 1/2016, 6/2016, 6/2017, 9/2018, 9/2019, 10/2020, 6/2021 Effective Date 9/1/2021; Oxford only: N/A 1. Background Step Therapy programs are utilized to encourage use of lower cost alternatives for certain therapeutic classes. a. Multi-Source Brand Products This program requires a member to try the A-rated generic prior to receiving coverage for Depakote, Depakote ER, Felbatol, Keppra, Keppra XR, Lamictal, Lamictal ODT, Lamictal XR, Lyrica, Mysoline, Neurontin, Onfi, Sabril, Topamax, Trileptal and Zonegran. There will be exceptions for members with a documented diagnosis of a seizure disorder. For members with a claim for at least a 14 day supply of the A-rated generic in the previous 6 months, the prescription will process automatically. b. Modified Release Products This program requires a member to try levetiracetam immediate release, levetiracetam extended-release, levetiracetam solution, lamotrigine immediate release, divalproex sodium delayed release, Depakote delayed release, generic valproic acid, Depakene formulations, Depakote sprinkles, divalproex sodium sprinkles, oxcarbazepine or Trileptal prior to coverage of their respective modified release formulations: lamotrigine extended-release, lamotrigine orally disintegrating tablet, Oxtellar XR*, Qudexy XR*, Spritam and Trokendi XR*. -
Official Journal C161
ISSN 1725-2423 Official Journal C 161 of the European Union Volume 51 English edition Information and Notices 25 June 2008 Notice No Contents Page II Information INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES Commission 2008/C 161/01 Non-opposition to a notified concentration (Case COMP/M.5032 — Roxel/Protac) (1) ......................... 1 2008/C 161/02 Non-opposition to a notified concentration (Case COMP/M.5094 — Nokia/Trolltech) (1) ..................... 1 IV Notices NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES Council 2008/C 161/03 Notification by Romania concerning visa reciprocity .................................................................... 2 2008/C 161/04 Notification by Romania concerning visa reciprocity .................................................................... 3 Commission 2008/C 161/05 Euro exchange rates ............................................................................................................... 4 2008/C 161/06 Final report of the Hearing Officer in Case COMP/M.4781 — Norddeutsche Affinerie/Cumerio (Pursuant to Articles 15 and 16 of Commission Decision 2001/462/EC, ECSC of 23 May 2001 on the terms of reference of Hearing Officers in certain competition proceedings — OJ L 162, 19.6.2001, p. 21) ............................. 5 EN (1) Text with EEA relevance (Continued overleaf) 1 Notice No Contents (continued) Page 2008/C 161/07 Opinion of the Advisory Committee on Mergers given at its meeting of 9 January 2008 regarding a draft decision relating to Case COMP/M.4781 — Norddeutsche -
UMICORE SA (GROUP) Brussels - Belgium | Manufacture of Basic Precious and Other Non- 2020 Ferrous Metals Significant Operations in at Least One Risk Country
EcoVadis Scorecard www.ecovadis.com UMICORE SA (GROUP) Brussels - Belgium | Manufacture of basic precious and other non- 2020 ferrous metals Significant operations in at least one risk country Publication date: 24 Jul 2020 Valid until: 24 Jul 2021 CSR Performance Insufficient Partial Moderate Advanced Outstanding Average score OVERALL SCORE ENVIRONMENT LABOR & HUMAN ETHICS SUSTAINABLE RIGHTS PROCUREMENT 73 /100 80 /100 80 /100 60 /100 60 /100 99th Weight Weight Weight Weight percentile Overall score distribution Theme score comparison 100 UMICORE SA (GROUP) ENVIRONMENT LABOR & HUMAN 100% 80 73 RIGHTS 60 75% 40 20 50% 50.36 41.55 25% 0% 4.36 3.74 SUSTAINABLE ETHICS 0 0 25 45 65 85 100 PROCUREMENT All companies assessed by EcoVadis in this industry UMICORE SA (GROUP) score All companies assessed by EcoVadis in this industry Strengths and Improvement Areas Environment Weight Strengths (38) Policies Strengths Quantitative objectives set on some relevant issues [i.e. GHG emissions, water] Comprehensive policy on a majority of environmental issues Endorsement of external initiative on environmental issues [i.e. The International Platinum Group Metals Association (IPA), Eurometaux, CIRAF, Fachvereinigung Edelmetalle] Actions Strengths Company-specific emergency preparedness and response procedure regarding local pollution Measures to minimize odor generation in rendering plant operations Control measures to monitor and/or prevent contamination of groundwater Measures to reduce CO2 emissions from transport Formalized procedure related to materials / chemicals management (e.g. storing, handling, transportation) Purchasing of renewable energy Registration of substances to the ECHA Reuse by-products from the process as raw materials or as raw material substitutes in other processes Monitoring of pollutant concentrations into waste gas (e.g. -
Investor Presentation June 2021
Umicore Investor Presentation June 2021 Introduction to Umicore We are a global materials technology and recycling group One of three global A leading supplier of key The world’s leading leaders in emission control materials for rechargeable recycler of complex waste catalysts for light-duty and batteries used in electrified streams containing heavy-duty vehicles and transportation and portable precious and other for all fuel types electronics valuable metals 3 With a unique position in clean mobility materials and recycling Internal Plug-In Hybrid Combustion Engine Electric Vehicle Umicore provides: Umicore provides: Emission control catalysts Battery cathode materials and emission control catalysts Full Electric Vehicle Fuel cells Umicore provides: Umicore provides: Battery cathode materials Electro-catalyst and battery cathode materials Present across all drive trains and offering sustainable closed- loop services 4 Built on sound foundations Supportive Unique business Industry leader in megatrends & model sustainability legislation resource scarcity more stringent emission control electrification recyclingrecycling of the automobile We help improve air quality, make electrified transport possible and tackle resource scarcity 5 5 Unique position in Automotive Catalysts CATALYSIS Strong growth drivers: Umicore best positioned to Tightening emission norms for capture growth in growing LDV and HDD, in particular in gasoline segment; technology China, Europe and India leader in cGPF platforms in China and Europe Significant value uplift -
Umicore 2020 FY Presentation
Umicore FY 2020 performance 11 February 2021 Overview Highlights 2020 2021 outlook Maintaining strategic course while responding effectively to COVID-19 crisis 2020 business review 2020 financial review Wrap-up Q&A Umicore FY 2020 performance 2 Highlights 2020 Record earnings in unprecedented conditions ENERGY & SURFACE CATALYSIS TECHNOLOGIES RECYCLING Significant impact of pandemic Impact of pandemic on several end-markets Record performance with a on automotive market in H1 nearly doubling of adj. EBIT Umicore disproportionately Excluding impact of excess YoY, reflecting strong growth exposed to market recovery in inventories, Umicore’s EV across all business units H2 due to strong position in cathode materials volumes grew gasoline for LDV broadly in line with EV battery Exceptional metal price demand environment Strict cost management and operational excellence Adj. EBIT reflecting underutilized High activity levels despite initiatives capacity and pricing pressure in COVID-19 crisis and favorable China, as well as costs related to trading conditions recent and ongoing expansions Umicore FY 2020 performance 3 2021 outlook 2021 outlook Umicore expects to achieve substantial growth in earnings in 2021, with growth in all business Groups Given the current limited visibility, this outlook statement is made under the assumption that the ongoing COVID-19 outbreak would not result in additional material or protracted disruptions to the economy or Umicore’s operations CATALYSIS ENERGY & SURFACE RECYCLING TECHNOLOGIES Substantial growth in sales volumes of Favorable metal prices Further benefit from leading edge cathode materials for EVs technology offering in gasoline Supportive supply mix and applications for LDV in China and Persisting Chinese overcapacity and moderate volume growth in Europe pricing pressure Precious Metals Refining Initial impact of China VI legislation Some € 50m increase in fixed costs in If current elevated metal price for HDD applications Rechargeable Battery Materials levels were to prevail throughout the year, Adj.